Short answer
RxSight, Inc. (RXST) filed an 8-K current report with the SEC on July 15, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). CEO transition effective July 20, 2026: Aziz Mottiwala replaces Ron Kurtz, who becomes Chief Medical Officer after leading since 2016.
RxSight, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CEO transition effective July 20, 2026: Aziz Mottiwala replaces Ron Kurtz, who becomes Chief Medical Officer after leading since 2016
- Mottiwala brings commercial leadership from Tarsus, Opiant, Avanir, and Allergan, potentially emphasizing commercialization execution
- New CEO compensation: $750,000 salary, bonus up to 90%, and $14 million equity inducement package
- Kurtz retains $740,000 salary, up to 100% bonus eligibility, four $370,000 retention bonuses, and 500,000 RSUs
- Board turnover accompanies succession: Mottiwala becomes Class II director through 2029, while Kurtz resigns without dispute; inducement plan reserves 3,500,000 shares
Item 7.01 · Regulation FD Disclosure
- Mottiwala appointed President and CEO, marking a leadership transition at RxSight
- Dr. Kurtz transitioning to Chief Medical Officer, retaining a medical and clinical leadership role
- CEO change may affect strategic priorities, execution, and investor confidence
- Exhibit 99.1 contains the company’s announcement and additional transition details
Item EX-99.1 · Exhibit EX-99.1
- Leadership transition effective July 20, 2026, with Aziz Mottiwala becoming President and CEO
- Ron Kurtz, M.D. moving to Chief Medical Officer, preserving founder-level product and clinical expertise
- Kurtz resigning from the Board; Mottiwala joining, concentrating commercial leadership and board succession
- Mottiwala’s eye-care commercialization background signals emphasis on scaling adoption of RxSight’s adjustable-lens platform
- Previously communicated financial guidance unchanged, limiting immediate earnings-impact implications
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RxSight, Inc. 8-K filings
Get the next RXST 8-K as it lands
Follow RXST for push alerts, or ask the research agent what this filing means.